Submit Your Request Now
- Panel Features
- Panels List
- Workflow
- Why Creative Proteomics
- Demo
- Sample Requirements
- FAQ
What is the Olink Flex Customized Immuno-Oncology Panel
Customized panel for human
The Olink Flex Customized Immuno-Oncology Panel leverages multiplex proteomics technology to simultaneously measure 21 critical biomarkers involved in tumor-immune system interactions, covering essential cytokines and emerging targets, with a minimal requirement of 1μL plasma/serum and capacity for 40 samples per run. The platform delivers exceptional sensitivity (<1 pg/mL detection threshold) and precision (<5% inter-assay CV) via NPX normalization. Scientists can personalize their research by choosing 15-21 analytes from a pool of 208 rigorously validated immune-related proteins, allowing customized exploration of immuno-oncological processes. This adaptable system enables detailed examination of immune modulation pathways across diverse experimental models while upholding Olink's stringent quality benchmarks. The panel provides researchers with a robust tool for in-depth characterization of tumor microenvironment dynamics and host immune reactions in basic and translational studies.
Features of the pane
- Species: Human proteome analysis.
- Design: Customizable via Olink Insight.
- Proteins: 21 biomarkers characterizing tumor development and the immune response.
- Sample: 1 µL plasma/serum.
- Readout: NPX-normalized quantification.
- Platform: Olink Signature Q100 platform exclusive.
List of 21 Human Derived Biomarkers
Protein category
The Olink Flex Customized Immuno-Oncology Panel quantifies 21 strategically selected protein biomarkers organized into key functional categories: Immune Checkpoint Regulators, Cytokine/Chemokine Signaling Molecules, Tumor Microenvironment Factors, T-cell Activation Markers, Angiogenesis Regulators, Apoptosis-Related Proteins, and Immune Cell Recruitment Factors (see Table. List of Olink Flex Customized Immuno-Oncology Panel). These targets encompass human proteins involved in fundamental biological mechanisms relevant to tumor-immune interactions, covering processes such as immune cell infiltration, antigen presentation, immunosuppressive signaling, cytotoxic response modulation, and intercellular communication networks. The panel incorporates rigorously validated biomarkers associated with PD-1/PD-L1 axis regulation, interferon response pathways, and lymphocyte differentiation through systematic literature review and experimental verification, offering researchers a comprehensive solution for high-throughput proteomic studies in cancer immunology and immunotherapy mechanism research.
Table. List of Olink Flex Customized Immuno-Oncology Panel
| UniProt ID | Gene | Protein name | Customized Olink Flex panel |
| P01375 | TNFα | Tumor necrosis factor | Immuno-oncology |
| P01579 | IFNγ | Interferon gamma | Immuno-oncology |
| P15018 | LIF | Leukemia inhibitory factor | Immuno-oncology |
| P05231 | IL6 | Interleukin-6 | Immuno-oncology |
| P10145 | IL8 | Interleukin-8 | Immuno-oncology |
| P22301 | IL10 | Interleukin-10 | Immuno-oncology |
| O75144 | B7H2 | ICOS ligand | Immuno-oncology |
| P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | Immuno-oncology |
| P40933 | IL15 | Interleukin-15 | Immuno-oncology |
| P18627 | FDC | Lymphocyte activation gene 3 protein | Immuno-oncology |
| Q9BQ51 | PDL2 | Programmed cell death 1 ligand 2 | Immuno-oncology |
| Q15116 | PD1 | Programmed cell death protein 1 | Immuno-oncology |
| P15692 | VEGF-A | Vascular endothelial growth factor A | Immuno-oncology |
| P14210 | HGF | Hepatocyte growth factor | Immuno-oncology |
| Q99616 | CCL13 | C-C motif chemokine 13 | Immuno-oncology |
| P09341 | CXCL1 | Growth-regulated alpha protein | Immuno-oncology |
| P02778 | CXCL10 | C-X-C motif chemokine 10 | Immuno-oncology |
| Q07325 | CXCL9 | C-X-C motif chemokine 9 | Immuno-oncology |
| O14625 | CXCL11 | C-X-C motif chemokine 11 | Immuno-oncology |
| P01730 | CD4 | T-cell surface glycoprotein CD4 | Immuno-oncology |
| P10144 | GRB | Granzyme B | Immuno-oncology |
Protein Functions
Biological process
principally involved in critical biological processes governing antitumor immunity, including T-cell activation and differentiation, immune checkpoint regulation, cytokine-mediated signaling cascades, chemotactic leukocyte recruitment, cytotoxic effector functions, angiogenesis modulation, and tumor microenvironment remodeling.
Disease area
particularly support scientific investigation across multiple cancer research areas, including tumor-immune evasion mechanisms, lymphocyte infiltration dynamics, angiogenesis regulation, and metastatic microenvironment studies.
The Application of Olink Flex Customized Immuno-Oncology Panel.
The Olink Flex Customized Immuno-Oncology Panel enables precise quantification of tumor-immune interactions-associated biomarkers, providing researchers with a powerful tool for:
- Characterization of tumor-immune microenvironment dynamics, including cytokine networks, immune checkpoint interactions, and lymphocyte activation states in experimental models;
- Investigation of immune evasion mechanisms through systematic profiling of immunosuppressive factors (e.g., PD-1), chemotactic signals, and T-cell exhaustion markers;
- Discovery of biomarker signatures associated with immune cell infiltration patterns and therapeutic response pathways in preclinical studies.
Workflow of Olink Proteomics
Why Creativ Proteomics
Disease-Focused Frameworks
Preconfigured workflows for tumor-immune interactions (e.g., checkpoint regulation, cytokine networks).
Customizable Design
42 flexible assay slots complementing 208 validated immune targets for tailored study configurations.
Multi-Omics Compatibility
Seamless integration with transcriptomic, proteomic, and metabolomic datasets.
Comprehensive Biomarker Coverage
Targets key pathways: immune evasion, T-cell activation, angiogenesis, and chemotaxis.
Demo Results of Olink Data
Figure 1: Baseline circulating LIF levels predict outcomes in cancer patients receiving anti-PD-l1 immunotherapy – results from an independently validated cohort. ( Loriot, Y., et al. 2021)
Figure 2: Serum immunoproteomics dynamics correlated with preoperative chemotherapy efficacy. (Tang, Z.., et al. 2023)
Sample Requirements
| Sample Type | Recommended Sample Size | Sample Quality | Pre-treatment and Storage | Sample Transport |
| Plasma/Serum/Body Fluid | Sample volume: 40 µL minimum | Target: 0.5–1 mg/mL protein | Distribute into sterile vials; freeze at -80°C | Dry ice shipment (-80°C) for foil-sealed samples |
| Tissue | ||||
| Cells | ||||
| Exosomes | ||||
| Other |
FAQs
What are the components of the Olink Flex sample controls?
The panel uses triplicate pooled human plasma controls supplemented with recombinant proteins for key immuno-oncology targets. These controls monitor inter-plate variation, validate assay precision (<5% CV), and ensure consistent NPX quantification across batches.
How were the Flex Customized Immuno-Oncology panel's biomarkers selected?
Biomarkers were curated through:
- Public databases (UniProt, Gene Ontology) for tumor-immune pathway relevance
- Expert review of immune checkpoint, cytokine, and T-cell activation networks
- Rigorous antibody validation for specificity, sensitivity, and reproducibility
What research applications does the Olinnk Flex Customized Immuno-Oncology panel support?
- Tumor-immune microenvironment characterization (e.g., PD-1/PD-L1 axis, chemokine networks),
- Mechanistic studies of immune evasion and T-cell exhaustion.
- Preclinical therapeutic research (e.g., cytokine signaling modulation).
Can the Olink Flex panel be customized?
Yes, researchers can select 15–21 analytes from 208 validated immune markers to focus on specific pathways (e.g., angiogenesis, lymphocyte recruitment).
References
- Loriot, Y., Marabelle, A., Guégan, J. P., et al. (2021). Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Annals of oncology: official journal of the European Society for Medical Oncology, 32(11), 1381–1390. https://doi.org/10.1016/j.annonc.2021.08.1748
- Tang, Z., Gu, Y., Shi, Z., et al. (2023). Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. Cell reports. Medicine, 4(2), 100931. https://doi.org/10.1016/j.xcrm.2023.100931